CA2599959A1 - Method of treating depression, mood disorders and anxiety disorders using neuromodulation - Google Patents

Method of treating depression, mood disorders and anxiety disorders using neuromodulation Download PDF

Info

Publication number
CA2599959A1
CA2599959A1 CA002599959A CA2599959A CA2599959A1 CA 2599959 A1 CA2599959 A1 CA 2599959A1 CA 002599959 A CA002599959 A CA 002599959A CA 2599959 A CA2599959 A CA 2599959A CA 2599959 A1 CA2599959 A1 CA 2599959A1
Authority
CA
Canada
Prior art keywords
area
disorder
stimulation
mood
catheter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002599959A
Other languages
French (fr)
Inventor
Helen S. Mayberg
Andres M. Lozano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Neuromodulation Systems Inc
Original Assignee
Functional Neuroscience Inc.
Helen S. Mayberg
Andres M. Lozano
Northstar Neuroscience, Inc.
Advanced Neuromodulation Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Functional Neuroscience Inc., Helen S. Mayberg, Andres M. Lozano, Northstar Neuroscience, Inc., Advanced Neuromodulation Systems, Inc. filed Critical Functional Neuroscience Inc.
Publication of CA2599959A1 publication Critical patent/CA2599959A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526Head electrodes
    • A61N1/0529Electrodes for brain stimulation
    • A61N1/0531Brain cortex electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526Head electrodes
    • A61N1/0529Electrodes for brain stimulation
    • A61N1/0534Electrodes for deep brain stimulation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36082Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36082Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
    • A61N1/36096Mood disorders, e.g. depression, anxiety or panic disorder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/05General characteristics of the apparatus combined with other kinds of therapy
    • A61M2205/054General characteristics of the apparatus combined with other kinds of therapy with electrotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • A61M2205/3507Communication with implanted devices, e.g. external control
    • A61M2205/3523Communication with implanted devices, e.g. external control using telemetric means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00Anatomical parts of the body
    • A61M2210/06Head
    • A61M2210/0693Brain, cerebrum

Abstract

The present invention involves a method and a system for using electrical stimulation and/or chemical stimulation to treat an affective disorder, such as depression. More particularly, the method comprises surgically implanting an electrical stimulation lead and/or catheter that is in communication with a predetermined site which is coupled to a signal generator and/or infusion pump that release either an electrical signal and/or a pharmaceutical resulting in stimulation of the predetermined site thereby treating the mood and/or anxiety.

Description

METHOD OF TREATING DEPRESSION, MOOD DISORDERS AND ANXIETY
DISORDERS USING NEUROMODULATION

[0001] The present invention claims priority to U.S. Provisional Patent Application Serial No. 60/657,518, filed March 1, 2005, which is incorporated by reference herein in its entirety.

TECHNICAL FIELD ' [0002] This invention relates to nervous tissue stimulation for treating depression, anxiety disorders and mood disorders, and more particularly to modulating nervous tissue at a predetermined stimulation site in brain tissue.

BACKGROUND OF THE INVENTION
[0003] Recent estimates indicate that more than 19 million Americans over the age of 18 years experience a depressive illness each year. The American Psychiatric Association recognizes several types of clinical depression, including Mild Depression (Dysthymia), Major Depression, and Bipolar Disorder (Manic-Depression). Major Depression is defined by a constellation of chronic symptoms that include sleep problems, appetite problems, anhedonia or lack of energy, feelings of worthlessness or hopelessness, difficulty concentrating, and suicidal thoughts. Approximately 9.2 million Americans suffer from Major Depression, and approximately 15 percent of all people who suffer from Major Depression take their own lives.
Bipolar Disorder involves major depressive episodes alternating with high-energy periods of rash behavior, poor judgment, and grand delusions. An estimated one percent of the American population experiences Bipolar Disorder annually.
[0004] Significant advances in the treatment of depression have been made in the past decade. Since the introduction of selective serotonin reuptake inhibitors (SSRIs), i.e., Prozac , many patients have been effectively treated with anti-depressant medication. New medications to treat depression are introduced almost every year, and research in this area is ongoing. However, an estimated 10 to 30 percent of depressed patients taking an anti-depressant are partially or totally resistant to the treatment. Those who suffer from treatment-resistant depression have almost no alternatives. Thus, there is a need to develop alternative treatments for these patients.
[0005] The use of electrical stimulation for treating neurological disease, including such disorders as movement disorders including Parkinson's disease, essential tremor, dystonia, and chronic pain, has been widely discussed in the literature. It has been recognized that electrical stimulation holds significant advantages over lesioning since lesioning destroys the nervous system tissue. In many instances, the preferred effect is to modulate neuronal activity.
Electrical stimulation permits such modulation of the target neural structures and, equally importantly, does not require the destruction of nervous tissue. Such electrical stimulation procedures include electroconvulsive therapy (ECT), repetitive transcranial (rTMS) magnetic stimulation and vagal nerve stimulation (VNS).
[0006] Efforts have been made to treat psychiatric disorders with peripheral/cranial nerve stimulation. Recently, partial benefits with vagus nerve stimulation in patients with depression have been described in U.S. Pat. No. 5,299,569. Another example of electrical stimulation to treat depression is described in U.S. Pat. No. 5,470,846, which discloses the use of transcranial pulsed magnetic fields to treat depression. Yet further, U.S.
Pat. No. 5,263,480 describes that stimulation of the vagus nerve may control depression and compulsive eating disorders and U.S. Pat. No. 5,540,734 teaches stimulation of the trigeminal or glossopharyngeal nerves for psychiatric illness, such as depression.
[0007] Deep brain stimulation (DBS) has been applied to the treatment of central pain syndromes and movement disorders, and it is currently being explored as a therapy for epilepsy. For instance, U.S. Pat. No. 6, 016,449 and U.S. Pat. No. 6,176,242 disclose a system for the electrical stimulation of areas in the brain for the treatment of certain neurological diseases such as epilepsy, migraine headaches and Parkinson's disease.
[0008] Various electrical stimulation and/or drug infusion devices have been proposed for treating neurological disorders. Some devices stimulate through the skin, such as electrodes placed on the scalp. Other devices require significant surgical procedures for placement of electrodes, catheters, leads, and/or processing units. These devices may also require an external apparatus that needs to be strapped or otherwise affixed to the skin.
[0009] However, despite the aforesaid available treatments, there are patients with major depression that remain treatment refractory and chronically disabled.
For these severely ill and disabled patients, novel therapies are required.

BRIEF SUMMARY OF THE INVENTION
[0010] The present invention relates to electrical and/or chemical stimulation applied to areas of the brain not considered in the prior art to play a role in depression. In certain embodiments, the invention uses electrical stimulation and/or chemical stimulation (i.e., one or more pharmaceuticals) to treat depression. In addition to electrical and/or chemical stimulation, magnetic stimulation can also be used, such as transcranial magnetic stimulation ("TMS").
According to one embodiment of the invention, the stimulation modulates areas of the brain that exhibit altered activity in patients relative to psychiatrically normal control subjects, thereby treating or preventing affective disorders, for example depression and/or anxiety disorders. Such stimulation is likely to be produced by electrical stimulation, an excitatory neurotransmitter agonist(s) (i.e., norepinephrine), an inhibitory neurotransmitter antagonist(s), and/or a medication that increases the level of an excitatory neurotransmitter (i.e., flouxetine (Prozac ), trazodone).
[0011] In addition to electrical and/or chemical stimulation, magnetic stimulation, ultrasonic stimulation and/or thermal stimulation can also be used. Magnetic stimulation can be provided by internally implanted probes or by externally applied directed magnetic fields.
Thermal stimulation can be provided by using implanted probes that are regulated to produce or emit heat and/or cold temperatures.
[0012] Alternatively, affective disorders can be treated by utilizing other known methods to alter the neuronal activity of the above mentioned predetermined sites. For example, lesioning and mechanical disruption can be used as described by US Patent Numbers 6,629,973, 3,653,385, which is incorporated herein by reference in its entirety.
[0013] One embodiment of the present invention utilizes neurosurgical intervention to modulate neuronal activity in patients suffering from depression or other affective disorders.
Such interventions include, applying electrical stimulation, herein termed "deep brain stimulation" or DBS, as is currently practiced to treat a number of disorders like Parkinson's disease. Other stimulations can include chemical stimulation such as through the use of pharmaceutical or drug pumps, for example local delivery of neuroactive substances to disrupt or block the pathological activity stemming from or coursing through this area.
It is envisioned that such stimulation (i.e., electrical, magnetic, chemical, thermal and/or ultrasonic) modulates the gray matter and white matter tracts in a predetermined area.
[0014] The predetermined site or target area can include but are limited to the subgenual cingulate area (Brodmann area 25), hypothalamus, orbital frontal cortex (Brodmann area 32/Brodmann area 10), anterior insula, medial frontal cortex (mFr;
Brodmann area 10), dorsolateral prefrontal (Brodmann area 9/46), dorsal anterior cortex (Brodmann area 24), posterior cingulate area (Brodmann area 31), premotor (Brodmann area 6), orbital frontal (Brodmann area 11Brodmann area 10), parietal region (Brodmann area 40), ventrolateral prefrontal (Brodmann area 47), dorsal cingulate (Brodmann area 24b), dorsal anterior cingulate (Brodmann area 24) caudate nucleus, anterior thalamus (aThal), nucleus accumbens; frontal pole, periaqueductal gray area, brainstem and/or the surrounding or adjacent white matter tracts leading to or from the all of these listed areas or white matter tracts that are contiguous. Thus, stimulation of any of the above brain tissue areas, as well as any white matter tracts afferent to or efferent from the abovementioned brain tissue can result in alterations or changes that alleviate or improve the affective disorder of the subject. Still further, other stimulations may comprise magnetic stimulation and/or transplantation of cells.
[0015] Certain embodiments of the present invention involve a method that comprises surgically implanting a device or stimulation system in communication with a predetermined site. The device or stimulation system is operated to stimulate the predetermined site thereby treating the mood and/or anxiety disorder. The device or stimulation system may include a probe, for example, an electrode assembly (i.e., electrical stimulation lead), pharmaceutical-delivery assembly (i.e., catheters) or combinations of these (i.e., a catheter having at least one electrical stimulation lead) and/or a signal generator or signal source (i.e., electrical signal source, chemical signal source (i.e., pharmaceutical delivery pump) or magnetic signal source). The probe may be coupled to the electrical signal source, pharmaceutical delivery pump, or both which, in turn, is operated to stimulate the predetermined treatment site.
Yet further, the probe and the signal generator or source can be incorporated together, wherein the signal generator and probe are formed into a unitary or single unit, such unit may comprise, one, two or more electrodes. These devices are known in the art as microstimulators, for example, BionTM which is manufactured by Advanced Bionics Corporation.
[0016] Stimulation of the above mentioned predetermined areas includes stimulation of the gray matter and white matter tracts associated therewith that results in an alleviation or modulation of the mood and/or anxiety disorder. Associated white matter tracts includes the surrounding or adjacent white matter tracts leading to or from or white matter tracts that are contiguous with the area. Modulating the predetermined brain tissue area via electrical and/or chemical stimulation (i.e., pharmaceutical) and/or magnetic stimulation can result in increasing, decreasing, masking, altering, overriding or restoring neuronal activity resulting in treatment of the mood and/or anxiety disorder. Yet fiuther, stimulation of a subcallosal area may result in modulation of neuronal activity of other areas of the brain, for example, Brodmann area, 24, Brodmann area 25, Brodmann area 10, Brodmann area 9, the hypothalamus the brain stem, orbital frontal cortex (Brodmann area 32/Brodmann area 10), anterior insula, medial frontal cortex, dorsolateral prefrontal (Brodmann area 9/46), posterior cingulate area (Brodmann area 31), premotor (Brodmann area 6), parietal region (Brodmann area 40), ventrolateral prefrontal (Brodmann area 47), caudate nucleus, anterior thalamus, nucleus accumbens;
periaqueductal gray area; and/or the surrounding or adjacent white matter tracts leading to or from the all of these listed areas or white matter tracts that are contiguous.
[0017] Another embodiment of the present invention comprises a method of treating the mood and/or anxiety disorder comprising the steps of: surgically implanting an electrical stimulation lead having a proximal end and a stimulation portion, wherein after implantation the stimulation portion is in communication with a predetermined site; the stimulation lead is coupled to or in communication with a signal generator;
and an electrical signal is generated using the signal generator to modulate the predetermined site thereby treating the mood and/or anxiety disorder. The mood disorder is selected from the group consisting of major depressive disorder, bipolar disorder, and dysthymic disorder. The anxiety disorder is selected from the group consisting of panic disorder, posttraumatic stress disorder, obsessive-compulsive disorder and phobic disorder.
[0018] In further embodiments, the method can comprise the steps of:
surgically implanting a catheter having a proximal end coupled to a pump and a discharge portion for infusing a dosage of a pharmaceutical, wherein after implantation the discharge portion of the catheter is in communication with the predetermined stimulation site; and operating the pump to discharge the pharmaceutical through the discharge portion of the catheter into the stimulation site thereby treating the mood and/or anxiety disorder. The pharmaceutical is selected from the group consisting of inhibitory neurotransmitter agonist, an excitatory neurotransmitter antagonist, an agent that increases the level of an inhibitory neurotransmitter, an agent that decrease the level of an excitatory neurotransmitter, and a local anesthetic agent. It is envisioned that chemical stimulation or pharmaceutical infusion can be preformed independently of electrical stimulation and/or in combination with electrical stimulation.
[0019] Another embodiment of the present invention is a method of treating a mood and/or anxiety disorder comprising the steps of: surgically implanting an electrical stimulation lead having a proximal end and a stimulation portion, wherein after implantation the stimulation portion is in communication with a predetermined site; surgically implanting a catheter having a proximal end coupled to a pump and a discharge portion for infusing a dosage of a pharmaceutical, wherein after implantation the discharge portion of the catheter is in communication with a predetermined infusion site; and coupling the proximal end of the lead to a signal generator; generating an electrical signal with the signal generator to modulate the predetermined site; and operating the pump to discharge the pharmaceutical through the discharge portion of the catheter into the infusion site thereby treating the mood and/or anxiety disorder.
[0020] Other embodiments of the present invention include a system for treating subjects with mood and/or anxiety disorders. The therapeutic system comprises an electrical stimulation lead that is implanted into the subject's brain. The electrical stimulation lead comprises at least one electrode that is in communication with a predetermined site and delivers electrical signals to the predetermined site in response to received signals;
and a signal generator that generates signals for transmission to the electrodes of the lead resulting in delivery of electrical signals to predetermined site thereby treating the mood and/or anxiety disorder. The electrical stimulation lead may comprise one electrode or a plurality of electrodes in or around the target area. Still further, the signal generator is implanted in the subject's body.
[0021] Another example of a therapeutic system is a catheter having a proximal end coupled to a pump and a discharge portion for infusing a dosage of a pharmaceutical, wherein after implantation the discharge portion of the catheter is in communication with a predetermined stimulation site; and a pump to discharge the pharmaceutical through the discharge portion of the catheter into the predetermined stimulation site thereby treating the mood and/or anxiety disorder.
[0022] Still further, another therapeutic system comprises a device that is surgically implanted into the subject such that the device is in communication with a predetermined site.
An exemplary device includes a microstimulator (i.e., BionTM manufactured by Advanced Bionics Corporation) in which the device contains a generating portion and at least one electrode in a single unit. In further embodiments, a lead assembly is associated with at least one electrode of the microstimulator such that the lead can stimulate the predetermined site not in direct contact with the microstimulator.
[0023] Other therapeutic systems include a probe that is in communication with the predetermined site and a device that stimulates the probe thereby treating the mood and/or anxiety disorder. The probe can be, for example, an electrode assembly (i.e., electrical stimulation lead), pharmaceutical-delivery assembly (i.e., catheters) or combinations of these (i.e., a catheter having at least one electrical stimulation lead). The probe is coupled to the device, for example, electrical signal source, pharmaceutical delivery pump, or both which, in turn, is operated to stimulate the predetermined treatment site.
[0024] The foregoing has outlined rather broadly the features and technical advantages of the present invention in order that the detailed description of the invention that follows may be better understood. Additional features and advantages of the invention will be described hereinafter which form the subject of the claims of the invention.
It should be appreciated that the conception and specific embodiment disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present invention. It should also be realized that such equivalent constructions do not depart from the invention as set forth in the appended claims. The novel features which are believed to be characteristic of the invention, both as to its organization and method of operation, together with further objects and advantages will be better understood from the following description when considered in connection with the accompanying figures. It is to be expressly understood, however, that each of the figures is provided for the purpose of illustration and description only and is not intended as a definition of the limits of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS
[0025] For a more complete understanding of the present invention, reference is now made to the following descriptions taken in conjunction with the accompanying drawings.
[0026] FIGS. 1A and 1 B illustrate example electrical stimulation systems.
[0027] FIGS. 2A-2D illustrate example electrical stimulation leads that may be used in the present invention.
[0028] FIG. 3 is a flowchart describing the general procedure.

DETAILED DESCRIPTION OF THE INVENTION
[0029] It is readily apparent to one skilled in the art that various embodiments and modifications can be made to the invention disclosed in this Application without departing from the scope and spirit of the invention.

1. Definitions [0030] As used herein, the use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one." Still further, the terms "having," "including," "containing" and "comprising" are interchangeable and one of skill in the art is cognizant that these terms are open ended terms.
Some embodiments of the invention may consist of or consist essentially of one or more elements, method steps, and/or methods of the invention. It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein.
[0031] As used herein the term "affective disorders" refers to a group of disorders that are commonly associated with co-morbidity of depression and anxiety symptoms.
[0032] As used herein the term "anxiety" refers to an uncomfortable and unjustified sense of apprehension that may be diffuse and unfocused and is often accompanied by physiological symptoms.

[00331 As used herein the term "anxiety disorder" refers to or connotes significant distress and dysfunction due to feelings of apprehension, guilt, fear, etc.
Anxiety disorders include, but are not limited to panic disorders, posttraumatic stress disorder, obsessive-compulsive disorder and phobic disorders.

[0034] As used herein, the term "Brodmann area 25" refers to the defined area of Brodmann area 25 as known by one of skill in the art, as well as the surrounding or adjacent white matter tracts leading to and from Brodmann area 25 and/or white matter tracts that are contiguous with Brodmann area 25. The surrounding or adjacent white matter can include up to approximately a 1 cm radius of Brodmann area 25.

[0035] As used herein, the term "Brodmann area 24" refers to the defined area of Brodmann area 24 as known by one of skill in the art, as well as the surrounding or adjacent white matter tracts leading to and from Brodmann area 24 and/or white matter tracts that are contiguous with Brodmann area 24. The surrounding or adjacent white matter can include up to approximately a 1 cm radius of Brodmann area 24.

[0036] As used herein, the term "Brodmann area 9" refers to the defined area of Brodmann area 9 as known by one of skill in the art, as well as the surrounding or adjacent white matter tracts leading to and from Brodmann area 9 and/or white matter tracts that are contiguous with Brodmann area 9. The surrounding or adjacent white matter can include up to approximately a 1 cm radius of Brodmann area 9.

[0037] As used herein, the term "Brodmann area 10" refers to the defined area of Brodmann area 10 as known by one of skill in the art, as well as the surrounding or adjacent white matter tracts leading to and from Brodmann area 10 and/or white matter tracts that are contiguous with Brodmann area 10. The surrounding or adjacent white matter can include up to approximately a 1 cm radius of Brodmann area 10.

[0038] As used herein the term "depression" refers to a morbid sadness, dejection, or melancholy.

[0039] As used herein, the term "in communication" refers to one or more electrical stimulation leads and/or catheters being adjacent, in the general vicinity, in close proximity, or directly next to, or in direct contact or directly in the predetermined stimulation site. Thus, one of skill in the art understands that the one or more electrical stimulation leads and/or catheters are "in communication" with the predetermined site of the brain if the stimulation results in a modulation of neuronal activity associated with a site. Still further, "in communication" with brain tissue encompasses surrounding or adjacent white matter tracts or fibers leading to and from the brain tissue and/or white matter tracts or fibers that are contiguous with the brain tissue.

[0040] As used herein the term "limbic system" encompasses the amygdala, hippocampus, septum, cingulate gyrus, cingulate cortex, hypothalamus, epithalamus, anterior thalamus, mammillary bodies, and fomix. The limbic system has connections throughout the brain, more particularly with the primary sensory cortices, including the rhinencephalon for smell, the autonomic nervous system via the hypothalamus, and memory areas.
Yet further, the limbic system is involved in mood, emotion and thought.

[0041] As used herein the term "mania" or "manic" refers to a disordered mental state of extreme excitement.

[0042] As used herein the term "mood" refers to an internal emotional state of a person.

[0043] As used herein the term "mood disorder" is typically characterized by pervasive, prolonged, and disabling exaggerations of mood and affect that are associated with behavioral, physiologic, cognitive, neurochemical and psychomotor dysfunctions. The major mood disorders include, but are not limited to major depressive disorder (also known as unipolar disorder), bipolar disorder (also known as manic depressive illness or bipolar depression), dysthymic disorder. Other mood disorders may include, but are not limited to major depressive disorder, psychotic; major depressive disorder, melancholic; major depressive disorder, seasonal pattern; postpartum depression; brief recurrent depression; late luteal phase dysphoric disorder (premenstrual dysphoria); and cyclothymic disorder.

[0044] As used herein the term "modulate" refers to the ability to regulate positively or negatively neuronal activity. Thus, the term modulate can be used to refer to an increase, decrease, masking, altering, overriding or restoring neuronal activity. Modulation of neuronal activity affects psychological and/or psychiatric activity of a subject.

[0045] As used herein, the term "neuronal" refers to a neuron which is a morphologic and functional unit of the brain, spinal column, and peripheral nerves.

[0046] As used herein, the term "pharmaceutical" refers to a chemical or agent that is used as a drug. Thus, the term pharmaceutical and drug are interchangeable.

[0047] As used herein, the term "stimulate" or "stimulation" refers to electrical, chemical, and/or magnetic stimulation that modulates the predetennined sites in the brain.

[0048] As used herein, the term "subcallosal area" includes the medial gray matter and white matter under the corpus callosum, as well as the white matter tracts that are associated with the subcallosal area. Associated white matter tracts includes the surrounding or adjacent white matter tracts leading to or from a subcallosal area or white matter tracts that are contiguous with the subcallosal area. For the purposes of the present invention, the subcallosal area includes the following gray matter and the white matter tracts, as well as the white matter tracts that are associated with or leading to or from the following areas: subgenual cingulate area, subcallosal gyrus area, ventral/medial prefrontal cortex area, ventral/medial white matter, Brodmann area 24, Brodmann area 25, and/or Brodmann area 10. The surrounding or adjacent white matter tracts can include up to approximately a 1 cm radius of the subcallosal area.

[0049] As used herein, the term "subgenual cingulate area" includes the gray matter and white matter tracts associated with the subgenual cingulate area, the white matter tracts that surround or adjacent to the subgenual cingulate area, or the white matter tracts that lead to or from the subgenual cingulate area. The subgenual cingulate area includes Brodmann area 10, Brodmann area 24 and Brodmann area 25. The surrounding or adjacent white matter can include up to approximately a 1 cm radius of the subgenual cingulate area.

[0050] As used herein, the term "treating" and "treatment" refers to modulating certain areas of the brain so that the subject has an improvement in the disease, for example, beneficial or desired clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. One of skill in the art realizes that a treatment may improve the disease condition, but may not be a complete cure for the disease.

II. Electrical Stimulation Devices [0051] FIGS. 1A and 1B illustrate example electrical stimulation systems or devices 10 used to provide deep brain stimulation. Stimulation system 10 generates and applies a stimulus to a target area of the brain. In general terms, stimulation system 10 includes an implantable pulse generating source, such as an electrical stimulation source 12, and an implantable electrode, for example an electrical stimulation lead 14. In operation, both of these primary components are implanted in the person's body. Stimulation source 12 is coupled to a connecting portion 16 of electrical stimulation lead 14. Stimulation source 12 controls the electrical signals transmitted to electrodes 18 located on a stimulating portion 20 of electrical stimulation lead 14, located adjacent the target brain tissue, according to suitable signal parameters (i.e., duration, intensity, frequency, etc.). A doctor, the patient, or another user of stimulation source may directly or indirectly input signal parameters for controlling the nature of the electrical stimulation provided.

[0052] Another exemplary stimulation system or device includes a microstimulator (i.e., BionTM, manufactured by Advanced Bionics Corporation) in which the device contains a signal generating portion and at least one electrode in a the same unit or single unit, as defined in U.S. Patents 6,051,017; 6,735,475; 6,735,474 and 6,782,292, each of which are incorporated herein in its entirety. In further embodiments, a lead assembly is associated with at least one electrode of the microstimulator such that the lead can stimulate the predetermined site not in contact with the microstimulator.

[0053] In one embodiment, as shown in FIG. 1 A, stimulation source 12 includes an implantable pulse generator (IPG). One of skill in the art is aware that any commercially available implantable pulse generator can be used in the present invention, as well as a modified version of any commercially available pulse generator. Thus, one of skill in the art would be able to modify an IPG to achieve the desired results. An exemplary IPG is one that is manufactured by Advanced Neuromodulation Systems, Inc., such as the Genesis System, part numbers 3604, 3608, 3609, and 3644. Another example of an IPG is shown in FIGURE 1B, which shows stimulation source 12 including an implantable wireless receiver.
An example of a wireless receiver may be one manufactured by Advanced Neuromodulation Systems, Inc., such as the Renew System, part numbers 3408 and 3416. The wireless receiver is capable of receiving wireless signals from a wireless transmitter 22 located external to the person's body.
The wireless signals are represented in FIGURE 1B by wireless link symbol 24.
A doctor, the patient, or another user of stimulation source 12 may use a controller 26 located external to the person's body to provide control signals for operation of stimulation source 12. Controller 26 provides the control signals to wireless transmitter 22, wireless transmitter 22 transmits the control signals and power to the wireless receiver of stimulation source 12, and stimulation source 12 uses the control signals to vary the signal parameters of electrical signals transmitted through electrical stimulation lead 14 to the stimulation site. An example wireless transmitter may be one manufactured by Advanced Neuromodulation Systems, Inc., such as the Renew System, part numbers 3508 and 3516.

[0054] FIGS. 2A through 2D illustrate example electrical stimulation leads 14 that may be used to provide electrical stimulation to an area of the brain, however, one of skill in the art is aware that any electrical lead may be used in the present invention. As described above, each of the one or more leads 14 incorporated in stimulation system 10 includes one or more electrodes 18 adapted to be positioned near the target brain tissue and used to deliver electrical stimulation energy to the target brain tissue in response to electrical signals received from stimulation source 12. A percutaneous lead 14, such as example leads shown in FIG. 2A-2D, includes one or more circumferential electrodes 18 spaced apart from one another along the length of lead 14. Circumferential electrodes 18 emit electrical stimulation energy generally radially in all directions.

III. Implantation of Electrical Stimulation Devices [0055] While not being bound by the description of a particular procedure, patients who are to have an electrical stimulation lead or electrode implanted into the brain, generally, first have a stereotactic head frame, such as the Leksell, CRW, or Compass, mounted to the patient's skull by fixed screws. However, frameless techniques may also be used. Subsequent to the mounting of the frame, the patient typically undergoes a series of magnetic resonance imaging sessions, during which a series of two dimensional slice images of the patient's brain are built up into a quasi- three dimensional map in virtual space. This map is then correlated to the three dimensional stereotactic frame of reference in the real surgical field.
In order to align these two coordinate frames, both the instruments and the patient must be situated in correspondence to the virtual map. The current way to do this is to rigidly mount the head frame to the surgical table. Subsequently, a series of reference points are established to relative aspects of the frame and the patient's skull, so that either a person or a computer software system can adjust and calculate the correlation between the real world of the patient's head and the virtual space model of the patient's MRI scans. The surgeon is able to target any region within the stereotactic space of the brain with precision (i.e., within 1 mm). Initial anatomical target localization is achieved either directly using the MRI images, or indirectly using interactive anatomical atlas programs that map the atlas image onto the stereotactic image of the brain. As is described in greater detail below, the anatomical targets may be stimulated directly or affected through stimulation in another region of the brain.

[0056] Stimulation of the subgenual cingulate area results in blood flow changes in other areas of the brain, for example other areas associated with the limbic-cortical system. See for example areas illustrated in Table 1, as well as those areas described in Mayberg et al.
(Neuron, 45:1-10, 2005); US Patent Application US 20050033379A1, and US
Provisional application No. 60/567332, each of which is incorporated herein by reference in its entirety.
Thus, it is within the purview of one of skill in the art to stimulate these identified areas, as well as the subgenual cingulate area, or any gray and/or white matter associated with the identified areas, more specifically, white matter tracts afferent to or efferent from the abovementioned brain tissue.

d O~ O~ ~D ~O pp N p N d p O N 00 p M M N N O O M N r -~ 00 --1 . 'C N N N m~ N~ v~~ N N N"O N N ct' N in r'p O O N p N 00 O~ d' 00 N "D N M~ M M ~ 00 d' ~~ m Vn M
~ U

oo M[~ 01 kn d' ~O
rA N 0 00 ~10 orn ~t O "o V) N t~ rn M cf) C*, cf) "tc> 00i, ~ti aNi m vvi cn d d ~F d~i cn d d M M cr1 d MM M M Vl d' CA
pa a axaaaxaxx r~axaaa~axx kn cy pO"r"Zr ~110 110 d~ rnrn N M - ~~ N N O~ ~ O~ d d~ N~O ~O M M
o cw w !!_!_!__ vva a aQ, N
y p O\O ~ N l0 ~O ~t cr M d O d O 00 "p 00 N cd 00 N'"~ N N M M d M N M ' N M
c) N oo o N M
i 7 O
00 d~ v~i N 't v ~
N p~p N~ p N MN N k N00 O N N CO M N iN ~
.,. U

rA VI cC 110 d' oll Vl \O l- "0 (01 Ln-~1 M ~O - -00 Q~ l- l~ --~ 41 00 ~ 00 O) ~--~
N O Zp tn l- Q~ O N l~
U d' M M V1 d' V V'1 V1 L
v~ ~ ~ i ~ i i d' d' V;
A o ot a a x a x xaa a x a a rx ~~4 O p ~ P~ N M M O O O OIS Q~ M M Q~ d d N\G l~

~ rn 0 rn a u N N ~t ~O O
~ N ,-~ ~ N N M O N p o0 ~II~ 'cJ N d' N dN- v~n Ln N N~
rA N

O~ fr~ N N M (V
C~ O
U~ I-c! kn N M00 O O~ ~O O~ M
p N 0 1 O N d: o0 V ai vl ri ~O ~O d M ~ ~ d d Vii ' ' ~, < Po \. , a a x ar~axaxa N C) C1 d' N
...
bo ,~ ~ en a a ~n v ~ ~ t a, b A
~
N
IL
N

P U
O

~ U
'd' cV '- ~ U ~' 0~ 00 00 O V~ ~O b a N
d d d N
bA

.~
Eb >

=c ~
C'O P.
U

[0057] In certain embodiments, the predetermined site or target area can include but are limited to the subgenual cingulate area (sgCg; Brodmann area 25), hypothalamus (Hth), orbital frontal cortex (OrbF; Brodmann area 32/Brodmann area 10), anterior insula (alns), medial frontal cortex (mFr; Brodmann area 10), dorsolateral prefrontal (DLFP;
Brodmann area 9/46), dorsal anterior cortex (Brodmann area 24), posterior cingulate area (Brodmann area 31), premotor (Brodmann area 6), orbital frontal (Brodmann area 11Brodmann area 10), parietal region (Brodmann area 40), ventrolateral prefrontal (VLPF; Brodmann area 47), dorsal cingulate (dCg; Brodmann area 24b), dorsal anterior cingulate (Brodmann area 24) caudate nucleus, anterior thalamus (aThal), nucleus accumbens (NAcc) frontal pole (Frpole);
periaqueductal gray area (PAG); brainstem; and/or the surrounding or adjacent white matter tracts leading to or from the all of these listed areas or white matter tracts that are contiguous.
Thus, stimulation of any of the above brain tissue areas, as well as any white matter tracts afferent to or efferent from the abovementioned brain tissue can result in alterations or changes that alleviate or improve the affective disorder of the subject.

[0058] Based upon the coordinates derived or described above, the electrical stimulation lead 14 can be positioned in the brain. Typically, an insertion cannula for electrical stimulation lead 14 is inserted through the burr hole into the brain, but a cannula is not required.
For example, a hollow needle may provide the cannula. The cannula and electrical stimulation lead 14 may be inserted together or lead 14 may be inserted through the cannula after the cannula has been inserted.

[0059] Once an electrical stimulation lead, such as lead 14, has been positioned in the brain, the lead is uncoupled from any stereotactic equipment present, and the cannula and stereotactic equipment are removed. Where stereotactic equipment is used, the cannula may be removed before, during, or after removal of the stereotactic equipment.
Connecting portion 16 of electrical stimulation lead 14 is laid substantially flat along the skull.
Where appropriate, any burr hole cover seated in the burr hole may be used to secure electrical stimulation lead 14 in position and possibly to help prevent leakage from the burr hole and entry of contaminants into the burr hole. Example burr hole covers that may be appropriate in certain embodiments are illustrated and described in co-pending U.S. Application Nos. 60/528,604 and 60/528,689, both filed December 11, 2003 and entitled "Electrical Stimulation System and Associated Apparatus for Securing an Electrical Stimulation Lead in Position in a Person's Brain", each of which are incorporated herein in its entirety.

[0060] Once electrical stimulation lead 14 has been inserted and secured, connecting portion 16 of lead 14 extends from the lead insertion site to the implant site at which stimulation source 12 is implanted. The implant site is typically a subcutaneous pocket formed to receive and house stimulation source 12. The implant site is usually positioned a distance away from the insertion site, such as near the chest, below the clavicle or alternatively near the buttocks or another place in the torso area. Once all appropriate components of stimulation system are implanted, these components may be subject to mechanical forces and movement in response to movement of the person's body. A doctor, the patient, or another user of stimulation source may directly or indirectly input signal parameters for controlling the nature of the electrical stimulation provided.

[0061] Although example steps are illustrated and described, the present invention contemplates two or more steps taking place substantially simultaneously or in a different order.
In addition, the present invention contemplates using methods with additional steps, fewer steps, or different steps, so long as the steps remain appropriate for implanting an example stimulation system into a person for electrical stimulation of the person's brain.

IV. Infusion pumps [0062] In further embodiments, it may be desirable to use a drug delivery system independent of or in combination with electrical stimulation of the brain.
Drug delivery may be used independent of or in combination with a lead/electrode to provide electrical stimulation and chemical stimulation. When used, the drug delivery catheter is implanted such that the proximal end of the catheter is coupled to a pump and a discharge portion for infusing a dosage of a pharmaceutical or drug. Implantation of the catheter can be achieved by combining data from a number of sources including CT, MRI or conventional and/or magnetic resonance angiography into the stereotactic targeting model. Thus, without being bound to a specific procedure, implantation of the catheter can be achieved using similar techniques as discussed above for implantation of electrical leads, which is incorporated herein. The distal portion of the catheter can have multiple orifices to maximize delivery of the pharmaceutical while minimizing mechanical occlusion. The proximal portion of the catheter can be connected directly to a pump or via a metal, plastic, or other hollow connector, to an extending catheter.

[0063] Any type of infusion pump can be used in the present invention. For example, "active pumping" devices or so-called peristaltic pumps are described in U.S. Pat. Nos.
4,692,147, 5,840,069, and 6,036,459, which are incorporated herein by reference in their entirety. Peristaltic pumps are used to provide a metered amount of a drug in response to an electronic pulse generated by control circuitry associated within the device.
An example of a commercially available peristaltic pump is SynchroMed implantable pump from Medtronic, Inc., Minneapolis, Minn.

[0064] Other pumps that may be used in the present invention include accumulator-type pumps, for example certain external infusion pumps from Minimed, Inc., Northridge, Calif.
and Infusaid implantable pump from Strato/Infusaid, Inc., Norwood, Mass.
Passive pumping mechanisms can be used to release an agent in a constant flow or intermittently or in a bolus release. Passive type pumps include, for example, but are not limited to gas-driven pumps described in U.S. Pat. Nos. 3,731,681 and 3,951,147; and drive-spring diaphragm pumps described in U.S. Pat. Nos. 4,772,263, 6,666,845, 6,620,151 which are incorporated by reference in its entirety. Pumps of this type are commercially available, for example, Model 3000 from Arrow International, Reading, Penn. and IsoMed from Medtronic, Inc., Minneapolis, Minn.;
AccuRx pump from Advanced Neuromodulation Systems, Inc., Plano, TX.

[0065] Instances in which chemical and electrical stimulation will be administered to the subject, a catheter having electrical leads may be used, similar to the ones described in U.S. Patent 6,176,242; 5,423,877; 5,458,631 and 5,119,832, each of which are incorporated herein by reference in its entirety.

V. Identifying a Subject with an Affective Disorder [0066] Subjects to be treated using the present invention can be selected, identified and/or diagnosed based upon the accumulation of physical, chemical, and historical behavioral data on each patient. One of skill in the art is able to perform the appropriate examinations to accumulate such data. One type of examination can include neurological examinations, which can include mental status evaluations, which can further include a psychiatric assessment. Other types of examinations can include, but are not limited to, motor exanzination, cranial nerve examination, and neuropsychological tests (i. e., Minnesota Multiphasic Personality Inventory, Beck Depression Inventory, or Hamilton Rating Scale for Depression).

[0067] In addition to the above examinations, imaging techniques can be used to determine normal and abnormal brain function that can result in disorders.
Functional brain imaging allows for localization of specific normal and abnormal functioning of the nervous system. This includes electrical methods such as electroencephalography (EEG), magnetoencephalography (MEG), single photon emission computed tomography (SPECT), as well as metabolic and blood flow studies such as functional magnetic resonance imaging (fMRI), and positron emission tomography (PET) which can be utilized to localize brain function and dysfunction.

VI. Treatment of an Affective Disorder [0068] Initially, there is an impetus to treat psychiatric disorders with direct modulation of activity in that portion of the brain causing the pathological behavior. In this regard, there have been a large number of anatomical studies that have helped to identify the neural structures and their precise connections which are implicated in psychiatric activity/disorders. These are the structures that are functioning abnormally and manifesting in psychiatric/behavioral/addiction disorders. Numerous anatomical studies from autopsies, animal studies, and imaging such as computerized tomography (CT) scans, and magnetic resonance imaging (MRI) scans have demonstrated the role of these structures and their connections in psychiatric activity/disorders. In addition to these anatomical studies, a number of physiological techniques and diagnostic tools are used to determine the physiological aberrations underlying these disorders. This includes electrical methods such as electroencephalography (EEG), magnetoencephalography (MEG), as well as metabolic and blood flow studies such as functional magnetic resonance imaging (fMRI), and positron emission tomography (PET). The combination of the anatomical and physiological studies have provided increased insight into our understanding of the structures which are involved in the normal functioning or activity of the brain and the abnormal functioning manifesting in psychiatric, behavioral and addiction disorders.

[0069] Accordingly, the present invention relates to modulation of neuronal activity to affect psychological or psychiatric activity and/or mental activity. The present invention finds particular application in the modulation of neuronal function or processing to effect a functional outcome. The modulation of neuronal function is particularly useful with regard to the prevention, treatment, or amelioration of psychiatric, psychological, conscious state, behavioral, mood, and thought activity (unless otherwise indicated these will be collectively referred to herein as "psychological activity" or "psychiatric activity" or "mental activity"). When referring to a pathological or undesirable condition associated with the activity, reference may be made to "psychiatric disorder" or "psychological disorder"
instead of psychiatric or psychological activity. Although the activity to be modulated usually manifests itself in the form of a disorder such as a mood disorder (i.e., major depressive disorder, bipolar disorder, and dysthymic disorder) or an anxiety disorder (i.e., panic disorder, posttraumatic stress disorder, obsessive-compulsive disorder and phobic disorder), it is to be appreciated that the invention may also find application in conjunction with enhancing or diminishing any neurological or psychiatric function, not just an abnormality or disorder.
Psychiatric activity that may be modulated can include, but not be limited to, normal functions such as alertness, conscious state, drive, fear, anger, anxiety, euphoria, sadness, and the fight or flight response.

[0070] The present invention finds particular utility in its application to human psychological or psychiatric activity/disorder. However, it is also to be appreciated that the present invention is applicable to other animals which exhibit behavior that is modulated by the brain. This may include, for example, rodents, primates, canines, felines, elephants, dolphins, etc.
Utilizing the various embodiments of the present invention, one skilled in the art may be able to modulate the functional outcome of the brain to achieve a desirable result.

[0071] One technique that offers the ability to affect neuronal function is the delivery of electrical, chemical, and/or magnetic stimulation for neuromodulation directly to target tissues via an implanted device having a probe. The probe can be a stimulation lead or electrode assembly or drug-delivery catheter, or any combination thereof. The electrode assembly may be one electrode, multiple electrodes, or an array of electrodes in or around the target area. The proximal end of the probe can be coupled to a device, such as an electrical signal source, pharmaceutical delivery pump, or both which, in turn, is operated to stimulate the predetermined treatment site. In certain embodiments, the probe can be incorporated into the device such that the probe and the signal generating device are a single unit.

[0072] Certain embodiments of the present invention involve a method of treating a mood and/or anxiety disorder comprising the steps of: surgically implanting an electrical stimulation lead having a proximal end and a stimulation portion, wherein after implantation the stimulation portion is in communication with a predetermined site; coupling the proximal end of the lead to a signal generator; and generating an electrical signal with the signal generator to modulate the predetermined site thereby treating the mood and/or anxiety disorder.

[0073] In further embodiments, neuromodulation of the predetermined site of the present invention can be achieved using magnetic stimulation. One such system that can be employed and that is well known in the art is described in U.S. Patent 6,425,852, which is incorporated herein by reference in its entirety.

[0074] The therapeutic system or deep brain stimulation system of the present invention is surgically implanted as described in the above sections. One of skill in the art is cognizant that a variety of electrodes or electrical stimulation leads may be utilized in the present invention. It is desirable to use an electrode or lead that contacts or conforms to the target site for optimal delivery of electrical stimulation. One such example, is a single multi contact electrode with eight contacts separated by 2 1/2 mm each contract would have a span of approximately 2 mm. Another example is an electrode with two 1 cm contacts with a 2 mm intervening gap. Yet further, another example of an electrode that can be used in the present invention is a 2 or 3 branched electrode/catheter to cover the predetermined site or target site.
Each one of these three pronged catheters/electrodes have four contacts 1-2 mm contacts with a center to center separation of 2 of 2.5 mm and a span of 1.5 mm. Similar designs with catheters to infuse drugs with single outlet pore at the extremities of these types of catheters or along their shaft may also be designed and used in the present invention.

[0075] Still fu.rther, the present invention extends to methods of transplanting cells into a predetermined site to treat mood and/or anxiety disorders. It is envisioned that the transplanted cells can replace damaged, degenerating or dead neuronal cells, deliver a biologically active molecule to the predetermined site or to ameliorate a condition and/or to enhance or stimulate existing neuronal cells. Such transplantation methods are described in U.S.
Application No. US20040092010, which is incorporated herein by reference in its entirety.

[0076] Cells that can be transplanted can be obtained from stem cell lines (i.e., embryonic stem cells, non-embryonic stem cells, etc.) and/or brain biopsies, including tumor biopsies, autopsies and from animal donors. (See U.S. Application No.
US20040092010; U.S.
Pat. Nos. 5,735,505 and 6,251,669; Temple, Nature Reviews 2:513-520 (2000);
Bjorklund and Lindvall, Nat. Neurosci. 3:537-544 (2000)), each of which is incorporated herein by reference in its entirety). Brain stem cells can then be isolated (concentrated) from non-stem cells based on specific "marker" proteins present on their surface. In one such embodiment, a fluorescent antibody specific for such a marker can be used to isolate the stem cells using fluorescent cell sorting (FACS). In another embodiment an antibody affinity column can be employed.
Alternatively, distinctive morphological characteristics can be employed.

[0077] Alternatively, affective disorders can be treated by utilizing other known methods to alter the neuronal activity of the predetermined sites. For example, lesioning and mechanical disruption can be used as described by US Patent Numbers 6,629,973, 3,653,385, which is incorporated herein by reference in its entirety.

[0078] The predetermined site or target area can include but are limited to the subgenual cingulate area, hypothalamus, orbital frontal cortex, anterior insula, medial frontal cortex, dorsolateral prefrontal, dorsal anterior cortex, posterior cingulate area, premotor, orbital frontal, parietal region, ventrolateral prefrontal (Brodmann area 47), dorsal cingulate (Brodmann area 24b), dorsal anterior cingulate caudate nucleus anterior thalamus, nucleus accumbens;
periaqueductal gray area; brainstem, and/or the surrounding or adjacent white matter tracts leading to or from the all of these listed areas or white matter tracts that are contiguous. Still further, Bordmann areas that may be stimulated include Brodmann area 25, Brodmann area 10, Brodmann area 31, Brodmann area 9, Brodmann area 24b, Brodmann area 47, Brodmann area 32Brodmann area 10, Brodmann area 24, Brodmann area 46, Brodmann area 6, Brodmann area 32/ Brodmann area 11, Brodmann area 11/ Brodniann area 10, Brodmann area 46/
Brodmann area 6, and Brodmann area 39. Thus, stimulation of any of the above brain tissue areas, as well as any white matter tracts afferent to or efferent from the abovementioned brain tissue can result in alterations or changes that alleviate or improve the affective disorder of the subject.

[0079] Using the therapeutic stimulation system of the present invention, the predetermined site or target area is stimulated in an effective amount or effective treatment regimen to decrease, reduce, modulate or abrogate the mood and/or anxiety disorder. Thus, a subject is administered a therapeutically effective stimulation so that the subject has an improvement in the parameters relating to the affective disorder including subjective measures such as, for example, neurological examinations and neuropsychological tests (i.e., Minnesota Multiphasic Personality Inventory, Beck Depression Inventory, Mini-Mental Status Examination (MMSE), Hamilton Rating Scale for Depression, Wisconsin Card Sorting Test (WCST), Tower of London, Stroop task, MADRAS, CGI, N-BAC, or Yale-Brown Obsessive Compulsive score (Y-BOCS)), motor examination, and cranial nerve examination, and objective measures including use of additional psychiatric medications, such as anti-depressants, or other alterations in cerebral blood flow or metabolism and/or neurochemistry. The improvement is any observable or measurable improvement. Thus, one of skill in the art realizes that a treatment may improve the patient condition, but may not be a complete cure of the disease.

[0080] Treatment regimens may vary as well, and often depend on the health and age of the patient. Obviously, certain types of disease will require more aggressive treatment, while at the same time, certain patients cannot tolerate more taxing regimens.
The clinician will be best suited to make such decisions based on the known subject's history.

[0081] According to one embodiment of the present invention, the target site is stimulated using stimulation parameters such as, pulse width of about 1 to about 500 microseconds, more preferable, about 1 to about 90 microseconds; frequency of about 1 to about 300 Hz, more preferably, about 100 to about 185 Hz; and voltage of about 0.5 to about 10 volts, more preferably about 1 to about 10 volts. It is known in the art that the range for the stimulation parameters may be greater or smaller depending on the particular patient needs and can be determined by the physician. Other parameters that can be considered may include the type of stimulation for example, but not limited to acute stimulation, subacute stimulation, and/or chronic stimulation.

[0082] It is envisioned that stimulation of any of the above mentioned predetermined sites modulates other targets in the limbic-cortical circuit or pathway thereby improving any dysfunctional limbic-cortical circuits resulting in an improvement or alleviation or providing remission of depression and/or anxiety in the treated subjects.
Other such improvements can be sensations of calm, tranquility, peacefulness, increased energy and alertness, improved mood, improvement in attention and thinking, improvement in motor speed, improvement in mental speed and in spontaneity of speech, improved sleep, improved appetite, improved limbic behavior, increased motivation, decreases in anxiety, decreases in repetitive behavior, impulses, obsessions, etc.

[0083] For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether objective or subjective.

[0084] FIG. 3 summarizes the general procedure of the present invention. Any of the above described methods can be used to identify a subject or diagnose a subject that suffers from an affective disorder (100). Once the subject is identified, a stimulation device is implanted (200) into the subject such that the predetermined area of the subject's brain is stimulated (300).

After the target area has been stimulated (i.e., electrical, chemical, thermal magnetic and/or ultrasonic stimulation), the subject is evaluated to determine the change in the affective disorder.
One of skill in the art realizes that the present invention is not bound by the described methods or devices and that any method or device that would result in neuromodulation of the predetermined area could be used in the present invention.

VII. Combination Treatment [0085] In order to increase the effectiveness of the electrical stimulation method of the present invention, it may be desirable to combine electrical stimulation with chemical stimulation to treat the mood and/or anxiety disease.

[0086] In one preferred alternative, an implantable signal generator and electrical stimulating lead and an implantable pump and catheter(s) are used to deliver electrical stimulation and/or one or more stimulating drugs to the above mentioned areas as a treatment for mood and/or anxiety disorders.

[0087] Herein, stimulating drugs comprise medications, anesthetic agents, synthetic or natural peptides or hormones, neurotransmitters, cytokines and other intracellular and intercellular chemical signals and messengers, and the like. In addition, certain neurotransmitters, hormones, and other drugs are excitatory for some tissues, yet are inhibitory to other tissues. Therefore, where, herein, a drug is referred to as an "excitatory" drug, this means that the drug is acting in an excitatory manner, although it may act in an inhibitory manner in other circumstances and/or locations. Similarly, where an "inhibitory" drug is mentioned, this drug is acting in an inhibitory manner, although in other circumstances and/or locations, it may be an "excitatory" drug. In addition, stimulation of an area herein includes stimulation of cell bodies and axons in the area.

[0088] Similarly, excitatory neurotransmitter agonists (i.e., norepinephrine, epinephrine, glutamate, acetylcholine, serotonin, dopamine), agonists thereof, and agents that act to increase levels of an excitatory neurotransmitter(s) (i. e., edrophonium;
Mestinon; trazodone;
SSRIs (i.e., flouxetine, paroxetine, sertraline, citalopram and fluvoxamine);
tricyclic antidepressants (i.e., imipramine, amitriptyline, doxepin, desipramine, trimipramine and nortriptyline), monoamine oxidase inhibitors (i.e., phenelzine, tranylcypromine, isocarboxasid)), generally have an excitatory effect on neural tissue, while inhibitory neurotransmitters (i.e., dopamine, glycine, and gamma-aminobutyric acid (GABA)), agonists thereof, and agents that act to increase levels of an inhibitory neurotransmitter(s) generally have an inhibitory effect.
(Dopamine acts as an excitatory neurotransmitter in some locations and circumstances, and as an inhibitory neurotransmitter in other locations and circumstances.) However, antagonists of inhibitory neurotransmitters (i.e., bicuculline) and agents that act to decrease levels of an inhibitory neurotransmitter(s) have been demonstrated to excite neural tissue, leading to increased neural activity. Similarly, excitatory neurotransmitter antagonists (i.e., prazosin, and metoprolol) and agents that decrease levels of excitatory neurotransmitters may inhibit neural activity. Yet further, lithium salts and anesthetics (i.e., lidocane) may also be used in combination with electrical stimulation.

[0089] In addition to electrical stimulation and/or chemical stimulation, other forms of stimulation can be used, for example magnetic, or thermal, ultrasonic or combinations thereof. Magnetic stimulation can be provided by internally implanted probes or by externally applied directed magnetic fields, for example, U.S. Patent Nos. 6,592,509;
6,132,361; 5,752,911;
and 6,425,852, each of which is incorporated herein in its entirety. Thermal stimulation can be provided by using implanted probes that are regulated for heat and/or cold temperatures which can stimulate or inhibit neuronal activity, for example, U.S. Patent No.
6,567,696, which is incorporated herein by reference in its entirety.

VIII. Examples [0090] The following examples are included to demonstrate preferred embodiments, more particularly methods and procedures, of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice.
However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Example 1 Surgical Procedure [0091] Under local anesthesia, a stereotactic frame is first placed on the patient's head, followed by acquisition of an MRI (Magnetic Resonance Imaging) scan to localize the target region. Patients are then taken to the operating room where, under local anesthesia, two burr holes are placed behind the hairline. Stereotactic coordinates are derived from the pre-op MRI. The coordinates of this target arederived from the Schaltenbrand and Wahren Atlas.

[0092] Once the target sites are identified, two multi contact electrodes are delivered, one in each hemisphere. The electrodes are connected to a stimulating pulse generator.

[0093] With the patient's participation, each electrode contact is stimulated and acute changes in behavior are assessed using self report and mood rating scales, such as POMS, PANAS, sadness, anxiety and general well being, self-report, and mood, motor and cognitive scales, such as, finger tapping, verbal fluency. As either positive or negative changes in mood might occur, the relationship between the specific stimulation site and the resulting behavior is carefully documented. Following a testing session to help in optimal target selection and adjustment of the position of the electrode contacts, the incisions are closed and patients taken to the intensive care unit for recovery from surgery.

Example 2 Outpatient Programming and Clinical Follow-up [0094] Patients return for generator device programming. There were several parameters that are tested, namely, which electrode contact is to be stimulated, the polarity of stimulation, the frequency and pulse width of stimulation, etc.

[0095] The electrode programming is done on an outpatient basis and involves a series of trials over the course of a week. Electrode contacts that produced acute behavioral changes or fMRI signal changes in the target area are tried first. Once basic parameters are set, adjustments are made periodically until a stable program is established.

[0096] Once final stimulation parameters are established, psychiatric symptoms are monitored on a monthly basis. Clinical ratings are quantified using Beck, Hamilton, CGI, and Quality of Life Scales and Serial Neuropsychological Testing. Serial Neuropsychological Testing and PET studies are performed at time intervals following the procedure. General cognitive performance and detailed frontal lobe functioning is assessed. The test battery is designed to differentiate dorsolateral, superior medial, and ventrolateral/orbital frontal behaviors which is differently affected by activation or disruption of the target areas with electrical stimulation. Serial testing allowed differentiation between early surgical effects, chronic stimulation effects, and correlations with mood change.

REFERENCES
[0097] All patents and publications mentioned in the specifications are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

Bjorklund and Lindvall, Nat. Neurosci. 3:537-544 (2000) Drevets et al., Nature 386:824-7, 1997.
Ebmeier et al., Br J Psychiatry, 170:77-81, 1997.
Galynker et al., J Nucl Med., 39:608-12, 1998.
Temple, Nature Reviews 2:513-520 (2000) U.S. Pat. No. 3,731,681 U.S. Pat. No. 3,951,147 U.S. Pat. No. 4,692,147 U.S. Pat. No. 4,772,263 U.S. Pat. No. 5,119,832 U.S. Pat. No. 5,263,480 U.S. Pat. No. 5,299,569 U.S. Pat. No. 5,423,877 U.S. Pat. No. 5,458,631 U.S. Pat. No. 5,470,846 U.S. Pat. No. 5,540,734 U.S. Pat. No. 5,735,505 U.S. Pat. No. 5,840,069 U.S. Pat. No. 6, 016,449 U.S. Pat. No. 6,036,459 U.S. Pat. No. 6,051,017 U.S. Pat. No. 6,176,242 U.S. Pat. No. 6,251,669 U.S. Pat. No. 6,425,852 U.S. Pat. No. 6,609,031 U.S. Pat. No. 6,620,151 U.S. Pat. No. 6,666,845 U.S. Pat. No. 6,735,474 U.S. Pat. No. 6,735,475 U.S. Publication No. US200400920 10 [0098] Although the present invention and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the invention as defined by the appended claims.
Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the process, machine, manufacture, composition of matter, means, methods and steps described in the specification. As one will readily appreciate from the disclosure, processes, machines, manufacture, compositions of matter, means, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein may be utilized.
Accordingly, the appended claims are intended to include within their scope such processes, machines, manufacture, compositions of matter, means, methods, or steps.

Claims (8)

1. A method of treating a mood and/or anxiety disorder comprising the steps of:
surgically implanting an electrode in communication with a predetermined area;

coupling the electrode to a pulse generating source; and generating an electrical signal with the pulse generating source wherein said signal electrically stimulates the area thereby treating the mood and/or anxiety disorder.
2. The method of claim 1 further comprising the steps of:

surgically implanting a catheter having a proximal end coupled to a pump and a discharge portion for infusing a dosage of a pharmaceutical, wherein after implantation the discharge portion of the catheter is in communication with the area; and operating the pump to discharge the pharmaceutical through the discharge portion of the catheter into the area thereby treating the mood and/or anxiety disorder.
3. The method of claim 1, wherein the predetermined site is selected from the group consisting of orbital frontal cortex, anterior insula, medial frontal cortex, dorsolateral prefrontal area, posterior cingulate area, premotor cortex, parietal region, ventrolateral prefrontal cortex, caudate, anterior thalamus, nucleus accumbens (NAcc); periaqueductal gray area (PAG), and brainstem.
4. The method of claim 1, wherein the mood disorder is selected from the group consisting of major depressive disorder, bipolar disorder, and dysthymic disorder.
5. The method of claim 1, wherein the mood disorder is major depressive disorder.
6. The method of claim 1, wherein the anxiety disorder is selected from the group consisting of panic disorder, posttraumatic stress disorder, obsessive-compulsive disorder and phobic disorder.
7. The method of claim 2, wherein the pharmaceutical is selected from the group consisting of an inhibitory neurotransmitter agonist, an excitatory neurotransmitter antagonist, an agent that increases the level of an inhibitory neurotransmitter, an agent that decrease the level of an excitatory neurotransmitter, and a local anesthetic agent.
8. A method of treating a mood and/or anxiety disorder comprising the steps of:
surgically implanting an electrode in communication with a predetermined area;

surgically implanting a catheter having a proximal end coupled to a pump and a discharge portion for infusing a dosage of a pharmaceutical, wherein after implantation the discharge portion of the catheter is in communication with the area; and coupling the proximal end of the lead to a pulse generating source;

generating an electrical signal with the pulse generating source wherein said signal electrically stimulates the area; and operating the pump to discharge the pharmaceutical through the discharge portion of the catheter into the area thereby treating the mood and/or anxiety disorder.
CA002599959A 2005-03-01 2006-03-01 Method of treating depression, mood disorders and anxiety disorders using neuromodulation Abandoned CA2599959A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65751805P 2005-03-01 2005-03-01
US60/657,518 2005-03-01
PCT/US2006/007182 WO2006094015A2 (en) 2005-03-01 2006-03-01 Method of treating depression, mood disorders and anxiety disorders using neuromodulation

Publications (1)

Publication Number Publication Date
CA2599959A1 true CA2599959A1 (en) 2006-09-08

Family

ID=36941758

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002599959A Abandoned CA2599959A1 (en) 2005-03-01 2006-03-01 Method of treating depression, mood disorders and anxiety disorders using neuromodulation

Country Status (6)

Country Link
US (1) US9931500B2 (en)
EP (1) EP1863562A4 (en)
JP (1) JP2008535538A (en)
AU (1) AU2006218642A1 (en)
CA (1) CA2599959A1 (en)
WO (1) WO2006094015A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7305268B2 (en) 2000-07-13 2007-12-04 Northstar Neurscience, Inc. Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators
US7493171B1 (en) * 2000-11-21 2009-02-17 Boston Scientific Neuromodulation Corp. Treatment of pathologic craving and aversion syndromes and eating disorders by electrical brain stimulation and/or drug infusion
US9050469B1 (en) 2003-11-26 2015-06-09 Flint Hills Scientific, Llc Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals
US7613520B2 (en) 2004-10-21 2009-11-03 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat auditory dysfunction
US8565867B2 (en) 2005-01-28 2013-10-22 Cyberonics, Inc. Changeable electrode polarity stimulation by an implantable medical device
US8260426B2 (en) 2008-01-25 2012-09-04 Cyberonics, Inc. Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device
US9314633B2 (en) 2008-01-25 2016-04-19 Cyberonics, Inc. Contingent cardio-protection for epilepsy patients
US11779775B1 (en) * 2005-03-24 2023-10-10 Michael Sasha John Neurostimulation guided by brain network modeling
US7996079B2 (en) 2006-01-24 2011-08-09 Cyberonics, Inc. Input response override for an implantable medical device
US7657310B2 (en) 2006-01-26 2010-02-02 Cyberonics, Inc. Treatment of reproductive endocrine disorders by vagus nerve stimulation
US7801601B2 (en) 2006-01-27 2010-09-21 Cyberonics, Inc. Controlling neuromodulation using stimulus modalities
EP2026874B1 (en) 2006-03-29 2015-05-20 Dignity Health Vagus nerve stimulation system
US7869885B2 (en) 2006-04-28 2011-01-11 Cyberonics, Inc Threshold optimization for tissue stimulation therapy
US7962220B2 (en) 2006-04-28 2011-06-14 Cyberonics, Inc. Compensation reduction in tissue stimulation therapy
AU2007281122A1 (en) * 2006-08-02 2008-02-07 Advanced Neuromodulation Systems, Inc. Methods for treating neurological disorders, including neuropsychiatric and neuropsychological disorders, and associated systems
DK176782B1 (en) * 2006-08-04 2009-08-17 Innovision As Method for Compensating the Effect of Blood Soluble Gas Recirculation on Determination of Pulmonary Blood Flow in Repeat Inert Gas Repeat Tests
EP2069001B1 (en) * 2006-09-28 2013-02-20 Wisconsin Alumni Research Foundation Method and apparatus for promoting restorative sleep
US7869867B2 (en) 2006-10-27 2011-01-11 Cyberonics, Inc. Implantable neurostimulator with refractory stimulation
US8364273B2 (en) * 2007-04-24 2013-01-29 Dirk De Ridder Combination of tonic and burst stimulations to treat neurological disorders
US7869884B2 (en) 2007-04-26 2011-01-11 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7904175B2 (en) 2007-04-26 2011-03-08 Cyberonics, Inc. Trans-esophageal vagus nerve stimulation
US7962214B2 (en) 2007-04-26 2011-06-14 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7974701B2 (en) 2007-04-27 2011-07-05 Cyberonics, Inc. Dosing limitation for an implantable medical device
WO2009073891A1 (en) * 2007-12-07 2009-06-11 Northstar Neuroscience, Inc. Systems and methods for providing targeted neural stimulation therapy to address neurological disorders, including neuropyschiatric and neuropyschological disorders
US8337404B2 (en) 2010-10-01 2012-12-25 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US8571643B2 (en) 2010-09-16 2013-10-29 Flint Hills Scientific, Llc Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex
US8382667B2 (en) 2010-10-01 2013-02-26 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
DE102008015259B4 (en) * 2008-03-20 2010-07-22 Anm Adaptive Neuromodulation Gmbh Apparatus and method for auditory stimulation
US8204603B2 (en) 2008-04-25 2012-06-19 Cyberonics, Inc. Blocking exogenous action potentials by an implantable medical device
US8315703B2 (en) * 2008-04-30 2012-11-20 Advanced Neuromodulation Systems, Inc. Methods for targeting deep brain sites to treat mood and/or anxiety disorders
US8262714B2 (en) * 2008-08-05 2012-09-11 Advanced Neuromodulation Systems, Inc. Techniques for selecting signal delivery sites and other parameters for treating depression and other neurological disorders, and associated systems and methods
US8556940B2 (en) 2008-10-01 2013-10-15 Sherwin Hua System and method for wire-guided pedicle screw stabilization of spinal vertebrae
US8457747B2 (en) 2008-10-20 2013-06-04 Cyberonics, Inc. Neurostimulation with signal duration determined by a cardiac cycle
US8417344B2 (en) 2008-10-24 2013-04-09 Cyberonics, Inc. Dynamic cranial nerve stimulation based on brain state determination from cardiac data
US20100191304A1 (en) 2009-01-23 2010-07-29 Scott Timothy L Implantable Medical Device for Providing Chronic Condition Therapy and Acute Condition Therapy Using Vagus Nerve Stimulation
US8827912B2 (en) 2009-04-24 2014-09-09 Cyberonics, Inc. Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters
US8239028B2 (en) 2009-04-24 2012-08-07 Cyberonics, Inc. Use of cardiac parameters in methods and systems for treating a chronic medical condition
RU2012123549A (en) 2009-12-21 2014-01-27 Шервин ХУА INTRODUCTION OF MEDICAL DEVICES TO THE SKULL BY NON-ORTHOGONAL AND ORTHOGONAL TRAJECTORIES AND METHODS OF USE
US8649871B2 (en) 2010-04-29 2014-02-11 Cyberonics, Inc. Validity test adaptive constraint modification for cardiac data used for detection of state changes
US8831732B2 (en) 2010-04-29 2014-09-09 Cyberonics, Inc. Method, apparatus and system for validating and quantifying cardiac beat data quality
US8562536B2 (en) 2010-04-29 2013-10-22 Flint Hills Scientific, Llc Algorithm for detecting a seizure from cardiac data
US8679009B2 (en) 2010-06-15 2014-03-25 Flint Hills Scientific, Llc Systems approach to comorbidity assessment
US8641646B2 (en) 2010-07-30 2014-02-04 Cyberonics, Inc. Seizure detection using coordinate data
US8684921B2 (en) 2010-10-01 2014-04-01 Flint Hills Scientific Llc Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis
US9504390B2 (en) 2011-03-04 2016-11-29 Globalfoundries Inc. Detecting, assessing and managing a risk of death in epilepsy
US8725239B2 (en) 2011-04-25 2014-05-13 Cyberonics, Inc. Identifying seizures using heart rate decrease
US9402550B2 (en) 2011-04-29 2016-08-02 Cybertronics, Inc. Dynamic heart rate threshold for neurological event detection
US9549677B2 (en) 2011-10-14 2017-01-24 Flint Hills Scientific, L.L.C. Seizure detection methods, apparatus, and systems using a wavelet transform maximum modulus algorithm
US10448839B2 (en) 2012-04-23 2019-10-22 Livanova Usa, Inc. Methods, systems and apparatuses for detecting increased risk of sudden death
US10220211B2 (en) 2013-01-22 2019-03-05 Livanova Usa, Inc. Methods and systems to diagnose depression
US9446238B2 (en) * 2013-01-25 2016-09-20 Andres M. Lozano Deep brain stimulation of the subcallosal cingulate area for treatment of refractory anorexia nervosa
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CN110841134A (en) * 2018-08-20 2020-02-28 张海军 Automatic drug delivery system for treating Parkinson's disease
WO2020056418A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
US11160580B2 (en) 2019-04-24 2021-11-02 Spine23 Inc. Systems and methods for pedicle screw stabilization of spinal vertebrae
WO2023175610A1 (en) * 2022-03-13 2023-09-21 Graymatters Health Ltd. Depression treatment

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3731681A (en) * 1970-05-18 1973-05-08 Univ Minnesota Implantable indusion pump
US3653385A (en) * 1970-10-20 1972-04-04 Charles Burton Production of focal brain lesions by inductive heating
US3951147A (en) * 1975-04-07 1976-04-20 Metal Bellows Company Implantable infusate pump
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4883057A (en) * 1984-05-09 1989-11-28 Research Foundation, The City University Of New York Cathodic electrochemical current arrangement with telemetric application
US4772263A (en) * 1986-02-03 1988-09-20 Regents Of The University Of Minnesota Spring driven infusion pump
US5601835A (en) * 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5458631A (en) * 1989-01-06 1995-10-17 Xavier; Ravi Implantable catheter with electrical pulse nerve stimulators and drug delivery system
US5119832A (en) * 1989-07-11 1992-06-09 Ravi Xavier Epidural catheter with nerve stimulators
US5125888A (en) * 1990-01-10 1992-06-30 University Of Virginia Alumni Patents Foundation Magnetic stereotactic system for treatment delivery
US5342410A (en) * 1990-10-05 1994-08-30 Eric Braverman Apparatus and method for increasing the amplitude of P300 waves in the human brain
US5618531A (en) * 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5263480A (en) * 1991-02-01 1993-11-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
US5299569A (en) * 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5423877A (en) * 1992-05-04 1995-06-13 David C. Mackey Method and device for acute pain management by simultaneous spinal cord electrical stimulation and drug infusion
US5470846A (en) * 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders
US6129685A (en) * 1994-02-09 2000-10-10 The University Of Iowa Research Foundation Stereotactic hypothalamic obesity probe
US5853385A (en) 1994-08-26 1998-12-29 Cytotherapeutics, Inc. Encapsulated PC12 cell transplants for treatment of Parkinson's disease
US5540734A (en) * 1994-09-28 1996-07-30 Zabara; Jacob Cranial nerve stimulation treatments using neurocybernetic prosthesis
US6132361A (en) * 1994-11-28 2000-10-17 Neotonus, Inc. Transcranial brain stimulation
US6425852B1 (en) * 1994-11-28 2002-07-30 Emory University Apparatus and method for transcranial magnetic brain stimulation, including the treatment of depression and the localization and characterization of speech arrest
US5735505A (en) * 1995-04-03 1998-04-07 Data Connections, Inc. Cable pulley device and method
US5752911A (en) * 1995-04-27 1998-05-19 Canedo; Luis E. Electromagnetic method of treatment of epilepsy and apparatus
US7069634B1 (en) * 1995-04-28 2006-07-04 Medtronic, Inc. Method for manufacturing a catheter
WO1996033761A1 (en) * 1995-04-28 1996-10-31 Medtronic, Inc. Intraparenchymal infusion catheter system
US5585118A (en) * 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
US5753505A (en) * 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
US20020169485A1 (en) * 1995-10-16 2002-11-14 Neuropace, Inc. Differential neurostimulation therapy driven by physiological context
US6463328B1 (en) * 1996-02-02 2002-10-08 Michael Sasha John Adaptive brain stimulation method and system
US5611350A (en) 1996-02-08 1997-03-18 John; Michael S. Method and apparatus for facilitating recovery of patients in deep coma
WO1997029802A2 (en) * 1996-02-20 1997-08-21 Advanced Bionics Corporation Improved implantable microstimulator and systems employing the same
US5840069A (en) * 1996-04-04 1998-11-24 Medtronic, Inc. Implantable peristaltic pump techniques
US6036459A (en) * 1996-04-04 2000-03-14 Medtronic, Inc. Occlusion compensator for implantable peristaltic pump
US6094598A (en) * 1996-04-25 2000-07-25 Medtronics, Inc. Method of treating movement disorders by brain stimulation and drug infusion
US5716377A (en) * 1996-04-25 1998-02-10 Medtronic, Inc. Method of treating movement disorders by brain stimulation
US5683422A (en) * 1996-04-25 1997-11-04 Medtronic, Inc. Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation
US5735814A (en) * 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US5711316A (en) * 1996-04-30 1998-01-27 Medtronic, Inc. Method of treating movement disorders by brain infusion
US5713923A (en) * 1996-05-13 1998-02-03 Medtronic, Inc. Techniques for treating epilepsy by brain stimulation and drug infusion
US5921245A (en) * 1996-06-03 1999-07-13 O'donnell, Jr.; Francis E. Method for modification of anti-social behavior
US6609031B1 (en) * 1996-06-07 2003-08-19 Advanced Neuromodulation Systems, Inc. Multiprogrammable tissue stimulator and method
US6514937B1 (en) * 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US5873849A (en) * 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US5975085A (en) * 1997-05-01 1999-11-02 Medtronic, Inc. Method of treating schizophrenia by brain stimulation and drug infusion
US6128537A (en) * 1997-05-01 2000-10-03 Medtronic, Inc Techniques for treating anxiety by brain stimulation and drug infusion
US20040092010A1 (en) * 2002-04-15 2004-05-13 Ariel Ruiz I Altaba Method of proliferating and inducing brain stem cells to differentiate to neurons
US5938688A (en) * 1997-10-22 1999-08-17 Cornell Research Foundation, Inc. Deep brain stimulation method
US6597954B1 (en) * 1997-10-27 2003-07-22 Neuropace, Inc. System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes
US6016449A (en) * 1997-10-27 2000-01-18 Neuropace, Inc. System for treatment of neurological disorders
US6230049B1 (en) * 1999-08-13 2001-05-08 Neuro Pace, Inc. Integrated system for EEG monitoring and electrical stimulation with a multiplicity of electrodes
CA2318243A1 (en) * 1998-01-12 1999-07-15 Ronald P. Lesser Technique for using brain heat flow management to treat brain disorders
US6227203B1 (en) * 1998-02-12 2001-05-08 Medtronic, Inc. Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion
US6319241B1 (en) * 1998-04-30 2001-11-20 Medtronic, Inc. Techniques for positioning therapy delivery elements within a spinal cord or a brain
US6735474B1 (en) * 1998-07-06 2004-05-11 Advanced Bionics Corporation Implantable stimulator system and method for treatment of incontinence and pain
US6366813B1 (en) * 1998-08-05 2002-04-02 Dilorenzo Daniel J. Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease
SE520276C2 (en) 1999-01-25 2003-06-17 Elekta Ab Device for controlled tissue destruction
US6214016B1 (en) * 1999-04-29 2001-04-10 Medtronic, Inc. Medical instrument positioning device internal to a catheter or lead and method of use
US6176242B1 (en) * 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6353762B1 (en) * 1999-04-30 2002-03-05 Medtronic, Inc. Techniques for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve
US6161045A (en) 1999-06-01 2000-12-12 Neuropace, Inc. Method for determining stimulation parameters for the treatment of epileptic seizures
US6539263B1 (en) * 1999-06-11 2003-03-25 Cornell Research Foundation, Inc. Feedback mechanism for deep brain stimulation
US6567696B2 (en) * 2001-02-06 2003-05-20 Mediseb Ltd. Physiotherapeutic device
US6898455B2 (en) * 1999-10-29 2005-05-24 The Mclean Hospital Corporation Method for providing optimal drug dosage
US6907280B2 (en) * 1999-12-02 2005-06-14 The General Hospital Corporation Method and apparatus for objectively measuring pain, pain treatment and other related techniques
WO2001039664A1 (en) * 1999-12-02 2001-06-07 The General Hospital Corporation Method and apparatus for measuring indices of brain activity
US6609030B1 (en) * 2000-02-24 2003-08-19 Electrocore Techniques, Llc Method of treating psychiatric diseases by neuromodulation within the dorsomedial thalamus
US6418344B1 (en) * 2000-02-24 2002-07-09 Electrocore Techniques, Llc Method of treating psychiatric disorders by electrical stimulation within the orbitofrontal cerebral cortex
US6708064B2 (en) * 2000-02-24 2004-03-16 Ali R. Rezai Modulation of the brain to affect psychiatric disorders
US6473639B1 (en) * 2000-03-02 2002-10-29 Neuropace, Inc. Neurological event detection procedure using processed display channel based algorithms and devices incorporating these procedures
US6399574B1 (en) * 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US6353754B1 (en) * 2000-04-24 2002-03-05 Neuropace, Inc. System for the creation of patient specific templates for epileptiform activity detection
AU2001268473A1 (en) * 2000-06-20 2002-01-02 Advanced Bionics Corporation Apparatus for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion
US7305268B2 (en) 2000-07-13 2007-12-04 Northstar Neurscience, Inc. Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators
US7146217B2 (en) * 2000-07-13 2006-12-05 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a change in a neural-function of a patient
US7010351B2 (en) 2000-07-13 2006-03-07 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US6591138B1 (en) * 2000-08-31 2003-07-08 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
US6871098B2 (en) * 2000-10-30 2005-03-22 Medtronic, Inc. Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule
AU2002218012A1 (en) * 2000-11-14 2002-05-27 Joseph Manne Electromagnetically induced anesthesia and sensory stimulation
US6666845B2 (en) 2001-01-04 2003-12-23 Advanced Neuromodulation Systems, Inc. Implantable infusion pump
US6735475B1 (en) * 2001-01-30 2004-05-11 Advanced Bionics Corporation Fully implantable miniature neurostimulator for stimulation as a therapy for headache and/or facial pain
US6620151B2 (en) * 2001-03-01 2003-09-16 Advanced Neuromodulation Systems, Inc. Non-constant pressure infusion pump
US7112319B2 (en) * 2001-04-06 2006-09-26 The Research Foundation Of The City University Of New York Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using microelectrodes with microvoltammetry
WO2002087410A2 (en) 2001-04-27 2002-11-07 Yacov Naisberg Diagnosis, treatment and research of mental disorders
US8364278B2 (en) 2002-01-29 2013-01-29 Boston Scientific Neuromodulation Corporation Lead assembly for implantable microstimulator
US6592509B1 (en) * 2002-02-04 2003-07-15 Thomas W. Hunter, Jr. Electromagnetic stimulator
US7110820B2 (en) * 2002-02-05 2006-09-19 Tcheng Thomas K Responsive electrical stimulation for movement disorders
AU2004204674A1 (en) * 2003-01-03 2004-07-29 Advanced Neuromodulation Systems, Inc. System and method for stimulation of a person's brain stem
CA2432810A1 (en) * 2003-06-19 2004-12-19 Andres M. Lozano Method of treating depression, mood disorders and anxiety disorders by brian infusion
US7104947B2 (en) 2003-11-17 2006-09-12 Neuronetics, Inc. Determining stimulation levels for transcranial magnetic stimulation
US7981119B2 (en) * 2003-12-11 2011-07-19 Advanced Neuromodulation Systems, Inc. Electrical stimulation system and associated apparatus for securing an electrical stimulation lead in position in a person's brain
US7993352B2 (en) * 2003-12-11 2011-08-09 Advanced Neuromodulation Systems, Inc. Electrical stimulation system and associated apparatus for securing an electrical stimulation lead in position in a person's brain
US7353065B2 (en) 2004-09-14 2008-04-01 Neuropace, Inc. Responsive therapy for psychiatric disorders
WO2006094072A2 (en) 2005-03-01 2006-09-08 Functional Neuroscience Inc. Method of treating cognitive disorders using neuromodulation
US7774067B2 (en) 2006-04-12 2010-08-10 Medtronic, Inc. Autogeneration of neurostimulation therapy program groups
AU2007281122A1 (en) 2006-08-02 2008-02-07 Advanced Neuromodulation Systems, Inc. Methods for treating neurological disorders, including neuropsychiatric and neuropsychological disorders, and associated systems

Also Published As

Publication number Publication date
US9931500B2 (en) 2018-04-03
WO2006094015A2 (en) 2006-09-08
AU2006218642A1 (en) 2006-09-08
JP2008535538A (en) 2008-09-04
WO2006094015A3 (en) 2009-04-09
EP1863562A2 (en) 2007-12-12
US20060212091A1 (en) 2006-09-21
EP1863562A4 (en) 2009-10-21

Similar Documents

Publication Publication Date Title
US9931500B2 (en) Method of treating depression, mood disorders and anxiety disorders using neuromodulation
US9474852B2 (en) Method of treating depression, mood disorders and anxiety disorders using neuromodulation
AU2009200605B2 (en) Method of treating depression, mood disorders and anxiety disorders using neuromodulation
US7313442B2 (en) Method of treating mood disorders and/or anxiety disorders by brain stimulation
US8315703B2 (en) Methods for targeting deep brain sites to treat mood and/or anxiety disorders
US20160030666A1 (en) Method of treating cognitive disorders using neuromodulation
US8463387B2 (en) Stimulation of the amygdalohippocampal complex to treat neurological conditions
US9446238B2 (en) Deep brain stimulation of the subcallosal cingulate area for treatment of refractory anorexia nervosa
US20040172091A1 (en) Modulation of the brain to affect psychiatric disorders
US20080154332A1 (en) Modulation of the Brain to Affect Psychiatric Disorders and Functions
WO2008003318A1 (en) A research model system and a method for using electrical stimulation and/ chemical stimulation to induce depressive illness in research animals
AU2013200230A1 (en) Method of treating depression, mood disorders and anxiety disorders using neuromodulation
AU2004201821B2 (en) Method of treating mood disorders and/or anxiety disorders by brain stimulation
CA2466024A1 (en) Method of treating mood disorders and/or anxiety disorders by brain stimulation

Legal Events

Date Code Title Description
FZDE Dead